Abstract
We have previously shown that essential fatty acid (EFA) deficiency prevents diabetes and ameliorates insulitis in low-dose streptozotocin (LDS)-treated male CD-1 mice. The effects of EFA deficiency on the incidence of diabetes after LDS treatment has not been examined in other strains. In contrast to nighly susceptible CD-1 mice, several other strains of mice are only partially susceptible to LDS treatment and do not develop appreciable insulitis; however, the susceptibility of these strains can be markedly increased by cyclosporin A (CsA) pretreatment to reduce suppressor cell function. Weanling male BALB/cByJ, DBA/2J, and C57BL/6J mice were placed on EFA-deficient (EFAD) or control diets for 2 months and then divided into experimental and control groups. Ten EFAD and 10 control mice from each strain received LDS treatment (40 mg/kg/d 5d); an additional 10 EFAD BALB/cByJ and another 10 control BALB/cByJ mice received subcutaneous CsA injections (20 mg/kg/d) for 14 days prior to and for 5 days simultaneous with LDS treatment (40 mg/kg/d 5 d). Plasma glucose levels for all mice were determined 3 times per week for 3 weeks after LDS treatment. Mean plasma glucose levels (±SEM) at the end of the experiment were significantly lower in the EFAD groups vs control groups in BALB/cByJ (P<0.001), DBA/2J (P<0.00001), and C57BL/6J (P=0.012) mice. CsA supplementation increased the severity of diabetes in LDS-treated BALB/cByJ mice (P<0.0005); however, EFA deficiency also prevented diabetes in CsA-supplemented BALB/cByJ mice. Peri-insulitis was seen in 50% of control vs 40% of EFAD DBA/2J (NS) and in 20% of control vs 0% of EFAD C57BL/6J (NS) mice. Insulitis was not seen in either of these strains. Insulitis or peri-insulitis was seen in 10% of EFAD, 25% of EFAD+CsA, 33% of control, and 80% of control+CsA BALB/cByJ mice (P<0.05). We conclude that EFA deficiency prevents LDS-induced diabetes in all three of these partially susceptible strains as well as in BALB/cByJ mice augmented with CsA. EFA deficiency was confirmed biochemically on plasma samples.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Like AA, Rossini AA, Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193:415–417, 1976
Wilson GL, Leiter EH, Streptozotocin interactions with pancreatic B cells and the induction of insulin-dependent diabetes. Curr Top Microbiol Immunol 156:27–54, 1990
Kolb H, Mouse models of insulin dependent diabetes mellitus: low-dose streptozotocin-induced diabetes and nonobese diabetic (NOD) mice. Diabetes Metab Rev 3:751–778, 1987
Kolb H, Kröncke KD, Lessons from the low-dose streptozocin model in mice. Diabetes Rev 1:116–126, 1993
Rossini AA, Appel MC, Williams RM, Like AA, Genetic influence of the streptozotocin-induced insulitis and hyperglycemia. Diabetes 26:916–920, 1977
Leiter EH, Differential susceptibility of BALB/c sublines to diabetes induction by multi-dose streptozotocin treatment. Curr Top Microbiol Immunol 122:78–85, 1985
Kiesel U, Greulich B, Moume CM-S, Kolb H, Induction of experimental autoimmune diabetes by low-dose streptozotocin treatment in genetically resistant mice. Immunol Letters 3:227–230, 1981
Weide L, Lacy P, Smith H, Tung K, Adoptive transfer of lowdose streptozotocin autoimmune diabetes in a non-susceptible strain (abstract). Diabetes 40 [Suppl 1]:56A, 1991
Iwakiri R, Nagafuchi S, Kounoue S, Koga J, Nakayama M, Nakamura M, Niho Y, Cyclosporin A enhances streptozotocin-induced diabetes mellitus in CD-1 mice. Experientia 43:324–327, 1987
Linn T, Volkmann A, Germann H, Weoehrle M, Bretzel RG, Bicker U, Federlin K, Ciamexon in the low dose streptozotocin-induced diabetes in mice. Diabetes Res 6:113–117, 1987
Wright JR, Jr, Lefkowith JB, Schreiner G, Lacy PE, Essential fatty acid deficiency prevents multiple low-dose streptozotocin-induced diabetes in CD-1 mice. Proc Natl Acad Sci USA 85:6137–6141, 1988
Wright JR Jr, Haliburton B, Russell H, Henry M, Fraser R, Cook HW, The anti-diabetogenic effect of essential fatty acid deficiency in multiple low-dose streptozotocin-treated mice persists if essential fatty acid repletion occurs outside a brief window of susceptibility. Diabetologia 34:709–714, 1991
Lawen JG, Yu W, Cook HW, Wright JR Jr, Failure of donor essential fatty acid deficiency to prevent renal allograft rejection in rats. Transplantation 56:1269–1270, 1993
Lawen JG, Wright JR Jr Yu W, Epstein HR, Donor essential fatty acid deficiency does not prolong heterotopic cardiac allograft survival in rats. Transplantation 52:178–180, 1991
Holman R, The ratio of trienoic: tetraenoic acids in tissue lipids as a measure of essential fatty acid requirement. J Nutr 70:405–410, 1960
Andersson A, Islet implantation normalizes hyperglycaemia caused by streptozotocin-induced insulitis: experiments in mice. Lancet I:581–584, 1979
Weide L, Lacy P, Low-dose streptozotocin-induced autoimmune diabetes in an islet transplantation model. Diabetes 40:1157–1162, 1991
Kolb-Bachofen V, Epstein S, Kiesel U, Kolb H; Low-dose streptozotocin-induced diabetes in mice: electron microscopy reveals single cell insulitis before diabetes onset. Diabetes 37:21–27, 1988
Lefkowith JB, Essential fatty acid deficiency inhibits the in vivo generation of leukotriene B4 and suppresses levels of resident and elicited leukocytes in acute inflammation. J Immunol 140:228–233, 1988
Schreiner GF, Rovin B, Lefkowith JB, The anti-inflammatory effects of essential fatty acid deficiency in experimental glomerulonephritis. The modulation of macrophage migration and eicosanoid metabolism. J Immunol 143:3192–3199, 1989
Malaisse WJ, Malaisse-Lagae F, Sener A, Pipeleers DG, Determinants of the selective toxicity of alloxan to the beta cell. Proc Natl Acad Sci USA 79:927–930, 1982
Grankvist K, Marklund SL, Taljedal I-B, CuZn-superoxide dismutase MN-superoxide dismutase, catalase, and glutathione peroxidase in pancreatic islets and other tissues of the mouse. Biochem J 199:393–398, 1981
Mendola J, Wright JR Jr, Lacy PE, Oxygen free-radical scavengers and immune destruction of murine islets in allograft rejection and multiple low-dose streptozotocin-induced insulitis. Diabetes 38:379–385, 1989
Mandrup-Poulsen T, Helqvist S, Wogensen LD, Molvig J, Piciot F, Johannesen J, Nerup J, Cytokines and free radicals as effector molecules in the destruction of pancreatic beta cells. Curr Top Microbiol Immunol 164:169–193, 1990
Schreiner G, Rossini A, Mordes J, Handler E, Lacy P, Wright J, Lefkowith J, Essential fatty acid deficiency inhibits the development of diabetes in rats (abstract). Diabetes 37 [Suppl 1]:80A, 1988
Lenrow D, Luketich J, Naji A, Barker C, Immune modulation of the BB rats by essential fatty acid deficient (EFAD) diet (abstract). Diabetes 38 [Suppl 2]:74A
Lefkowith J, Schreiner G, Cormier J, Handler ES, Driscoll HK, Greiner D, Mordes JP, Rossini AA, Prevention of diabetes in the BB rat by essential fatty acid deficiency: relationship between physiological and biochemical changes. J Exp Med 171:729–743, 1990
Oschilewski M, Scwab E, Kiesel U, Opitz U, Stunkel K, Kolb-Bachofen V, Kolb H, Administration of silica or monoclonal anti-body to Thy-1 prevents low-dose streptozotocin-induced diabetes in mice. Immunol Lett 12:289–294, 1986
Yasunami R, Bach J-F, Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol 18:481–484, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wright, J.R., Fraser, R.B., Kapoor, S. et al. Essential fatty acid deficiency prevents multiple low-dose streptozotocin-induced diabetes in naive and cyclosporin-treated low-responder murine strains. Acta Diabetol 32, 125–130 (1995). https://doi.org/10.1007/BF00569571
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00569571